Mucoadhesive and muco-penetrating delivery systems for eradication of helicobacter pylori

Asian Journal of Pharmaceutics

Volumn 6, Issue 1, 2012, Pages 18-30

  Arora, Saahil ^a   Bisen, Gaurav ^a   Budhiraja, R D ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Colonization; eradication therapy; floating drug delivery; Helicobacter pylori; liposomes; muco penetrating nanoparticles; mucoadhesive systems; pH sensitive gel systems

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLARITHROMYCIN PLUS LANSOPRAZOLE; AMPICILLIN; AZITHROMYCIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CIMETIDINE; CLARITHROMYCIN; ERYTHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HELICIDE; LANSOPRAZOLE; LEVOFLOXACIN; LIPOSOME; METRONIDAZOLE; MICROSPHERE; MISOPROSTOL; NANOPARTICLE; OMEPRAZOLE; PENICILLIN G; RABEPRAZOLE; RANITIDINE; TINIDAZOLE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; DRUG DELIVERY SYSTEM; ERADICATION THERAPY; GEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYDRODYNAMICALLY BALANCED SYSTEM; MUCOADHESION DELIVERY SYSTEM; MUCOPENETRATING DELIVERY SYSTEM; NONHUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE;

EID: 84866273505     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.100127     Document Type: Review

References (97)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;342:1273-75.
2. Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol 2010;26:618-23.
3. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136:1863-73.
4. Blaser MJ, Atherton JC. Helicobacter pylori persistence: Biology and disease. J Clin Invest 2004;113:321-33. (Pubitemid 38544173)
5. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25. (Pubitemid 19038537)
6. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
7. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, De Boni M, et al. Regression of primary low grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7. (Pubitemid 23259233)
8. Targa AC, Cesar AC, Cury PM, Silva, AE. Apoptosis in different gastric lesions and gastric cancer: Relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Genet Mol Res 2007;6:554-65. (Pubitemid 350096890)
9. Mishra S, Singh V, Rao GRK, Dixit VK, Gulati AK, Nath G. Prevalence of Helicobacter pylori in asymptomatic subjects-A nested PCR based study. Infect Genet Evol 2008;8:815-9.
10. Singh V, Mishra S, Maurya P, Rao G, Jain AK, Dixit VK, et al. Drug resistance pattern and clonality in H. pylori strains. J Infect Develop Count 2009;3:130-6.
11. Endo H, Yoshida H, Ohmi N, Ohta K, Higuchi S. Localization of [14C] amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin. J Antimicrob Chemother 2001;48:923-6. (Pubitemid 33735333)
12. Endo H, Yoshida H, Ohmi N, Ohta K, Higuchi S, Suga T. Localization of [14C] clarithromycin in rat gastric tissue when administered with lansaprazole and amoxicillin. J Antimicrob Chemother 2002;50:285-8. (Pubitemid 34918863)
13. Schreiber S, Scheid P. Gastric mucus of the guinea pig: Proton carrier and diffusion barrier. Am J Physiol 1997;272:G63-70.
14. Worku ML, Sidebotham RL, Walker MM, Keshavarz T, Karim QN. The relationship between Helicobacter pylori motility, morphology and phaseof growth: Implications for gastric colonization and pathology. Microbiology 1999;145:2803-11. (Pubitemid 29485895)
15. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci USA 2009;106:1421-6.
16. Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, et al. Mucin gene expression in normal, preneoplastic, andneoplastic human gastric epithelium. Cancer 1995;55:2681-90.
17. Ozbek A, Ozbek E, Dursun H, Kalkan Y, Demirci T. Can Helicobacter pylori invade human gastric mucosa? An in vivo study using electron microscopy, immunohistochemical methods, and real-time polymerase chain reaction. J Clin Gastroenterol 2010;44:416-22.
18. Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonization of gnotobiotic piglets by Helicobacter pylori. J Med Microbiol 1992;37:123-7.
19. Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. InfectImmun 1994;62:3604-7. (Pubitemid 24264297)
20. Moran AP. Relevance of fucosylation and Lewis antigen expression in the bacterial gastroduodenal pathogen H. pylori. Carbonhydr Res 2008;343:1952-65.
21. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesion binding fucosylatedhisto-blood group antigens revealed by retagging. Science 1998;279:373-7. (Pubitemid 28063371)
22. Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Helicobacter pylori Sab Aadhesin in persistent infection and chronic inflammation. Science 2002;297:573-8. (Pubitemid 34815336)
23. Yamaoka Y. Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis. World J Gastroenterol 2008;14:4265-72.
24. Sheu BS, Sheu SM, Yang HB, Huang AH, Wu JJ. Host gastric Lewis expressions determine the bacterial density of babA2-genopositve H. pyloriinfection. Gut 2003;52:927-32.
25. Papini E, Zorrati M, Cover TL. In search of Helicobacter pylori Vac A mechanism of action. Toxin 2001;39:1757-67. (Pubitemid 32787007)
26. Iijima K, Sekin H, Kokie T, Imatani A, Ohara S, Shimosegawa T. Long term effect of H. pylori eradication on the reversibility of acid secretion in profound hydrochlorhydria. Aliment Pharmacol Ther 2004;19:1181-8. (Pubitemid 38746261)
27. Ghiara P. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997;65:4996-5002. (Pubitemid 27513542)
28. Rad R, Gerhard R, Lang M. The Helicobacter pylori blood group antigenbinding adhesin facilitates bacterial colonization and augments a nonspecific immune response. J Immunol 2002;168:3033-41. (Pubitemid 34211685)
29. Tannaes T, Bukholm IK, Bukholm G. High relative content of lysophospholipids of Helicobacter pylori mediates increased risk for ulcer disease. Immunol Med Microbiol 2005;44:17-23. (Pubitemid 40385110)
30. Jonge D, Durrani RZ, Rijpkema SG. Role of the Helicobacter pylori outermembrane proteins AlpA and AlpB in colonization of the guinea pig stomach. J Med Microbiol 2004;53:375-9. (Pubitemid 38586502)
31. Figueiredo C, Quint WG, Sanna R. Genetic organization and heterogeneity of the iceA locus of Helicobacter pylori. Gene 2000;246:59-68. (Pubitemid 30190161)
32. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005;128:833-48. (Pubitemid 40523536)
33. Kudo T, Nurgalieva ZZ, Conner ME, Crawford S, Odenbreit S, Haas R. Correlation between Helicobacter pyloriOipA protein expression and oipAgene switch status. J Clin Microbiol 2004;42:2279-81. (Pubitemid 38637865)
34. Pedrazzoli J Jr, Calafatti SA, Ortiz RA, Dias FE, Deguer M, Mendes FD, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001;36:1248-53. (Pubitemid 33027801)
35. Uygun A, Kadayifci A, Yesilova Z, Ates Y, Safali M, Ilgan S, et al. Poor efficacy of ranitidine bismuth citrate-based triple therapies for eradication. Indian J Gastroenterol 2007;26:174-7. (Pubitemid 350074981)
36. Bhatia SJ, Kulkarni SG. Cost effectiveness of Helicobactor pylori Eradication in India: To live and let live expensively?. Indian J Gastroenterol 1997;16:S25.
37. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashina K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among H. pylori isolates from Japan. Antimicrob Agent Chemother 2000;44:2214-6. (Pubitemid 30484458)
38. Ramteke S, Ganesh N, Bhattacharya A, Jain NK. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori. J Drug Targeting 2009;17:225-34.
39. Achtman M, Azuma T, Berg DE, Ito Y, Morelli G, Pan ZJ, et al. Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Mol Microbiol 1999;32:459-70. (Pubitemid 29233892)
40. Suerbaum S, Smith JM, Bapumia K, Morelli G, Smith NH, Dyrek EKI,et al. Free recombination within Helicobacter pylori. Proc Nat Acad Scien 1998;95:12619-24. (Pubitemid 28483814)
41. Mégraud F. H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004;53:1374.
42. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxicillin concentration after different oral application forms. Antimicrob Agents Chemother 1993;37:1506-9. (Pubitemid 23202381)
43. Moes AJ. Gastric retention systems for oral drug delivery. Business Briefing: Pharmatech; 2003. p. 157-9.
44. Krogel I, Bodmeier R. Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder. J Control Release 1999;61:43-50. (Pubitemid 29406078)
45. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: Effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur J Pharm Sci 2005;24:363-73. (Pubitemid 40283519)
46. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm 2002;241:279-92. (Pubitemid 34718029)
47. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Del Rev 2009;61:158-71.
48. Wilding IR, Davis SS, O'Hagan DT. Targeting of drugs and vaccines to the gut. Pharmacol Ther 1994;62:97-124. (Pubitemid 24234859)
49. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4735804, April 5,1988.
50. Kagan L, Hoffman A. Systems for region selective drug delivery in the gastrointestinal tract: Biopharmaceutical considerations. Expert Opin Drug Del 2008;5:681-92. (Pubitemid 351998257)
51. Nama M, Gonugunta CSR, Veerareddy PR. Formulation and evaluation of gastroretentive dosage forms of Clarithromycin. AAPS PharmSciTech 2008;9:231-37.
52. Thakkar VT, Shah PA, Soni TG, Parmar MY, Gohel MC, Gandhi TR. Fabrication and evaluation of levofloxacin hemihydrate floating tablet. Research in Pharmaceutical Sciences 2008;3:65-72.
53. Barhate SD, Patel MM, Patil AB, Pawar SR, Rathi SR.Formulation and optimization of controlled released floating tablets of Clarithromycin. J Pharm Res 2009;2:445-8.
54. Gnanaprakash K, Chandhrashekhar KB, Chetty CM. Floating tablets of Famotidine with natural polymer: An approach for gastric treatment. J Pharm Sci Res 2010;2:657-62.
55. Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: New data for reconsidering the controversy. J Pharm Sci 1994;83:18-24. (Pubitemid 24233723)
56. Vyas SP, Khar RK. Gastroretentive systems in: Controlled drug delivery: Concepts and advances. 1sted. New Delhi: Vallabh Prakashan; 2002. p.196-217.
57. Chitnis VS, Malshe VS, Lalla JK. Bioadhesive polymers-synthesis, evaluation and application in controlled release tablets. Drug Dev Ind Pharm 1991;17:879-92.
58. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm 2008;34:1246-66.
59. Cone RA. Mucus. In: Mucosal Immunology. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. 2nd ed. San Diego: Academic Press; 1999. p. 43-64
60. Lehr CM, Bodde HE, Bouwstra JA, Junginger HE. A surface energy analysis of mucoadhesion. II. Prediction of mucoadhesive performance by spreading coefficients. Eur J Pharm Sci 1993;1:19-30. (Pubitemid 24049931)
61. Wang J, Yoshihiko T, Yoshiharu D, Kazuhiro M, Yasuhiko T, Yashito I. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H. pylori. Drug Deliv 2000;7:237-43. (Pubitemid 32057556)
62. Mascher HJ, Kikuta C. Determination of amoxicillin in human serum and plasma by high-performance liquid chromatography and on-line post column derivatisation. J Chromatogr A 1998;812:221-6. (Pubitemid 28300435)
63. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39:5-12. (Pubitemid 27092263)
64. Chadha R, Kashid N, Jain DV. Kinetic studies of the degradation of an amino penicillin antibiotic (amoxicillin trihydrate) in aqueous solution using heat conduction microcalorimetry. J Pharm Pharmacol 2003;55:1495-503. (Pubitemid 37441355)
65. Liu Z, Lu W, Qian L, Zhang X, Zeng P, Pan J. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J ContRel 2007;102:135-44.
66. PatelJK, PatelMM. Stomach specific anti-Helicobacter pylori therapy: Preparation and evaluation of amoxicillin-loaded chitosan mucoadhesive microspheres. Curr Drug Del 2007;4:41-50. (Pubitemid 46066413)
67. Patel JK, Chavda Jr. Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy. J Microencapsul 2009;26:365-76.
68. Narkar M, Sher P, Pawar A. Stomach-specific controlled release gellan beads of acid-soluble drug prepared by ionotropic gelation method. AAPS PharmSciTech 2010;11:267-77.
69. Umamaheshwari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK. Floatingbioadhesive microspheres containing acetohydroxamic acid for the clearance of Helicobacter pylori. Drug Deliv 2002;9:221-33.
70. Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm Phamacol 2003;55:1607-13. (Pubitemid 38054390)
71. Ishak AHI, Gehanne ASA, Mortada ND. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy. J Cont Rel 2007;119:207-14. (Pubitemid 46754505)
72. Rajnikanth PS, Mishra B. Preparation and in vitro characterization of Gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharm 2007;57:413-27.
73. El. Nujumi AM, Dorrian CA, Chittajallu RS, Neithercut WD, McColl KE. Effect of inhibition of Helicobacter pylori urease activity of acetohydroxamic acid on serum gastrin in duodenal ulcer subjects. Gut 1991;32:866-70.
74. Rajnikanth PS, Balasubramaniam J, Mishra B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 2007;335:114-22. (Pubitemid 46482869)
75. Ramteke S, Jain NK. Clarithromycin and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. J Drug Targeting 2008;16:65-72.
76. Chang CH, Lin YH, Yeh CL, Chen YC, Chiou SF, Hsu YM, et al. Nanoparticles incorporated in pH-sensitive hydrogels asamoxicillin delivery for eradication of Helicobacter pylori. Biomacromolecules 2010;11:133-42.
77. Moogooee M, Ramezanzadeh H, Jasoori S, Omidi Y, Davaran S. Synthesis and in vitro studies of cross-linked hydrogel nanoparticlescontaining amoxicillin. J Pharm Sci 2011;100:1057-66.
78. Umamaheshwari RB, Jain NK. Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J ContRel 2004;99:27-40. (Pubitemid 39165731)
79. Bardonnet PL, Faivre V, Boullanger P, Ollivon M, Falson F. Glycosylated liposomes against Helicobacter pylori: Behavior in acidic conditions. Biochem Biophys Res Commun 2009;383:48-53.
80. Jain P, Jain S, Prasad KN, Jain SK, Vyas SP. Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection. Mol Pharm 2009;6:593-603.
81. Wong KH, Skelton SK, Feeley JC. Strain characterization and grouping of Campylobacter jejuna and Campylobacter coli by interaction with lectins. J Clin Microbiol 1986;23:407-10. (Pubitemid 16137727)
82. Ascencio F, Guruge JL, Ljungh A, Megraud F, Wei S, Wadstrm T. Lectin typing of Helicobacter pylori. In: Malfertheiner P, Ditschuneit H, editors. Helicobacter pylori, gastritis and peptic ulcer. Berlin: Springer Verlag; 2002, p.105-9.
83. Kellens JIC, Jacobs JA, Peumans WJ, Strobbersingh EE. The agglutination of a haemolytic streptococcus by lectins. J Med Microbiol 1993;39:440-8.
84. Khin MM, Hua JS, Ng HC, Wadstrom T, Bow H. Agglutination of Helicobacter pylori coccoids by lectins. World J Gastroenterol 2000;6:202-9. (Pubitemid 30223595)
85. Umamaheshwari RB, Jain NK. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target 2003;11:415-24. (Pubitemid 38455827)
86. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori. J Drug Target 2008;16:694-705.
87. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis-a pilot study. Scand J Gastroenterol 1998;24:49-54.
88. Sjostrom JE, Fryklund J, Kuhler T, Larsson H. In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. J Med Microbiol 1996;441:425-33.
89. Dawson M,Krauland E, Wirtz D, Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog 2004;20:851-7. (Pubitemid 38784024)
90. Lin YH, Chang CH, Wu YS, Hsu YM, Chiou SF, Chen YJ. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials 2009;30:3332-42.
91. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009;30:2591-7.
92. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009;106:19268-73.
93. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm 2007;68:526-34.
94. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001;14:201-7. (Pubitemid 32884316)
95. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JR, Alonso MJ. Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP Pharma Sci 1999;9:429-36.
96. van der Lubben IM, Verhoef JC, van Aelst A, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: Preparation, Characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001;22:687-94. (Pubitemid 32112293)
97. Arora S, Gupta S, Narang RK, Budhiraja RD. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as muco-penetrating delivery system for H. pylori. Sci Pharm 2011;79:673-94.